Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Riedinger

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Anticancer Research|January 12, 2000
MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patientsS Lizard-Nacol, P Genne, B Coudert, et al.
Colloids and Surfaces. B, Biointerfaces|June 30, 2018
Cellular interactions of functionalized superparamagnetic iron oxide nanoparticles on oligodendrocytes without detrimental side effects: Cell death induction, oxidative stress and inflammationS Sruthi, L Maurizi, T Nury, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 14, 2012
Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypesO Humbert, A Berriolo-Riedinger, J M Riedinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 13, 2006
CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric studyJ M Riedinger, J Wafflart, G Ricolleau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2007
Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcomeJ M Riedinger, F Bonnetain, J P Basuyau, et al.
Bulletin Du Cancer|October 1, 1996
[Feasability of the dose adjustment of continuous infusion administration over 120 hours of 5-fluorouracil associated with cisplatin]B Coudert, C De Gislain, J L Beltramo, et al.
Bulletin Du Cancer|November 21, 2000
[Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group]J P Basuyau, M P Blanc-Vincent, J M Bidart, et al.
Annales De Biologie Clinique|April 9, 2002
[Interpretation of the CA125 kinetics during first line chemotherapy of the ovarian cancer: methodological aspects and characteristic profiles]J M Riedinger, N Eche, J P Basuyau, et al.
Bulletin Du Cancer|October 2, 2001
[Standards, options and recommendations for blood tumor markers in thyroid cancers]M F Pichon, J P Basuyau, G Gory-Delabaere, et al.
British Journal of Cancer|August 14, 2003
Summary report of the Standards, Options and Recommendations for the use of serum tumour markers in breast cancer: 2000J P Basuyau, M P Blanc-Vincent, J M Bidart, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Anticancer Research|January 12, 2000
MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patientsS Lizard-Nacol, P Genne, B Coudert, et al.
Colloids and Surfaces. B, Biointerfaces|June 30, 2018
Cellular interactions of functionalized superparamagnetic iron oxide nanoparticles on oligodendrocytes without detrimental side effects: Cell death induction, oxidative stress and inflammationS Sruthi, L Maurizi, T Nury, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 14, 2012
Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypesO Humbert, A Berriolo-Riedinger, J M Riedinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 13, 2006
CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric studyJ M Riedinger, J Wafflart, G Ricolleau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2007
Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcomeJ M Riedinger, F Bonnetain, J P Basuyau, et al.
Bulletin Du Cancer|October 1, 1996
[Feasability of the dose adjustment of continuous infusion administration over 120 hours of 5-fluorouracil associated with cisplatin]B Coudert, C De Gislain, J L Beltramo, et al.
Bulletin Du Cancer|November 21, 2000
[Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group]J P Basuyau, M P Blanc-Vincent, J M Bidart, et al.
Annales De Biologie Clinique|April 9, 2002
[Interpretation of the CA125 kinetics during first line chemotherapy of the ovarian cancer: methodological aspects and characteristic profiles]J M Riedinger, N Eche, J P Basuyau, et al.
Bulletin Du Cancer|October 2, 2001
[Standards, options and recommendations for blood tumor markers in thyroid cancers]M F Pichon, J P Basuyau, G Gory-Delabaere, et al.
British Journal of Cancer|August 14, 2003
Summary report of the Standards, Options and Recommendations for the use of serum tumour markers in breast cancer: 2000J P Basuyau, M P Blanc-Vincent, J M Bidart, et al.
Pageof 5